Compare LBRX & OPRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LBRX | OPRA |
|---|---|---|
| Founded | 2015 | 1996 |
| Country | United States | Norway |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | 2025 | 2018 |
| Metric | LBRX | OPRA |
|---|---|---|
| Price | $47.00 | $18.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $46.60 | $21.50 |
| AVG Volume (30 Days) | 285.4K | ★ 347.3K |
| Earning Date | 05-06-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 4.61% |
| EPS Growth | ★ 98.22 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $21.29 |
| Revenue Next Year | N/A | $15.34 |
| P/E Ratio | ★ N/A | $13.62 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.40 | $11.71 |
| 52 Week High | $50.16 | $21.06 |
| Indicator | LBRX | OPRA |
|---|---|---|
| Relative Strength Index (RSI) | 56.39 | 43.16 |
| Support Level | $21.90 | $18.56 |
| Resistance Level | $49.65 | $19.58 |
| Average True Range (ATR) | 2.02 | 0.60 |
| MACD | -0.53 | -0.09 |
| Stochastic Oscillator | 30.43 | 35.66 |
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.
Opera Ltd is a consumer internet software company providing a diversified portfolio of high-performance web browsers and adjacent digital services to engaged user base The company has transitioned from browser developer to multi-faceted platform offering a products and services that include PC and mobile browsers, its Opera Gaming portals and development tools, Opera News content platforms, Opera Ads platform, as well as a number of AI and web3 products and services, such as MiniPay and Opera AI, to a user base.